Company intelligence / Profile preview
Arcturus Therapeutics
- Ownership
- Public · ARCT
- Employees
- ~124
- Development stage
- Phase 2
Overview
Arcturus has advanced a late-stage pipeline of mRNA-based medicines and vaccines. Its COVID‑19 vaccine Kostaive® received regulatory approval in Japan and the EU, marking the first commercial launch of a self-amplifying mRNA vaccine. The company’s rare disease programs—ARCT‑810 for OTCD and ARCT‑032 for cystic fibrosis—are both in Phase 2 clinical trials, with interim data expected in mid to late 2025. Early results show favorable safety profiles supporting continued development.[6][9]
- Therapeutic areas
- OncologyPulmonologyInfectious DiseasesMetabolic Disorders
- Modalities
- messenger RNA (mRNA)self-amplifying mRNA (sa-mRNA)small interfering RNA (siRNA)circular RNA (circRNA)antisense oligonucleotides (ASO)gene editing RNA/DNA therapeutics[7][10]
- Industry
- Biotech
Drug pipeline
11 assets10 more assets in the full pipeline.
Request access →Partnerships
Financials
- Market cap
- $419M
- Total revenue
- $3M
- Enterprise value
- $250.4M
Beyond the preview
Go deeper on Arcturus Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arcturus Therapeutics.